1,005
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Chemical composition and biological activities of Asimina triloba leaf essential oil

Pages 982-986 | Received 05 Jul 2008, Accepted 24 Aug 2008, Published online: 20 Aug 2009

Figures & data

Table 1. Chemical composition of Asimina triloba leaf essential oil.

Figure 1. Anticancer activity of A. triloba leaf essential oil against A549 (human lung carcinoma) and MDA-MB231 (human breast carcinoma) cell lines. The concentration inhibiting cell growth by 50% (IC50 value) is 29.5 ± 2.0 μg/mL for A549 and 39.0 ± 2.9 μg/mL for MDA-MB231. Selenite was used as positive control and exhibited an IC50 value of 12.6 ± 3.0 and 18.2 ± 4.0 μg/mL against A549 and MDA-MB231, respectively (data not shown). Results are expressed as cell growth (% of control) ± standard deviation of three replicates.

Figure 1.  Anticancer activity of A. triloba leaf essential oil against A549 (human lung carcinoma) and MDA-MB231 (human breast carcinoma) cell lines. The concentration inhibiting cell growth by 50% (IC50 value) is 29.5 ± 2.0 μg/mL for A549 and 39.0 ± 2.9 μg/mL for MDA-MB231. Selenite was used as positive control and exhibited an IC50 value of 12.6 ± 3.0 and 18.2 ± 4.0 μg/mL against A549 and MDA-MB231, respectively (data not shown). Results are expressed as cell growth (% of control) ± standard deviation of three replicates.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.